CClinicalTrials.gg
CompletedNCT01556399DUO/AMP-LSTUpdated Mar 27, 2025

Endoscopic Characteristics of Duodenal and Ampullary Lesions

An observational study in Duodenal Diseases, sponsored by Professor Michael Bourke. Completed at 1 site in Australia. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-03-27.

Sponsored by Professor Michael Bourke · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
350
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose is to investigate whether polyps that look different at endoscopy, have formed via different mutations and have different risks of turning into cancer.

Read the detailed description

Laterally spreading tumours (LSTs), are polyps that have a lateral extension along the duodenal wall with minimal vertical growth. It has become evident over the last few years that rather than being a single entity requiring an accumulation of mutations, Duodenal and ampullary cancer is in fact a heterogenous disease forming via multiple distinct genetic pathways. It is therefore hypothesised that different polyp types have different genetic abnormalities, and potentially form via distinct genetic pathways, although this theory has not been widely examined.

This knowledge would be important in furthering our understanding of the development of cancer. There is accumulating evidence that genetic abnormalities may be a better predictor of cancer behaviour than histological grade. Additionally, guidelines for endoscopy surveillance are currently a one size fits all approach that do not reflect the genetic heterogeneity of the disease and the knowledge that only 5% of polyps progress to cancer. Genetic studies may assess future cancer risk to a person in polyps once removed and plan surveillance endoscopy frequency.

02

Conditions studied

  • Duodenal Diseases

Keywords

  • Duodenal adenoma
  • Ampullary adenoma
03

In context

Lead sponsor

Professor Michael Bourke is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with Duodenal and/or ampullary adenomas or cancers.

Inclusion criteria

  • Intention to perform Endoscopic Mucosal Resection
  • Adenoma equal to or greater than 20mm
  • over 18 years of age
  • Able to give informed consent to involvement in trial

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Lactation: currently breastfeeding
  • Taken clopidogrel within 7 days
  • Taken warfarin within 5 days
  • Had full therapeutic dose unfractionated heparin within 6 hours
  • Had full therapeutic dose low molecular weight heparin (LMWH) within 12 hours
  • Known clotting disorder
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
350 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Duodenal adenomas

    Patients who consent to participate in this study will have a small sample of their adenoma and normal tissue sent for molecular testing.

    Other: Tissue Sampling

Interventions

  • OtherTissue Sampling

    A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.

06

What researchers measure

Primary outcomes

  1. Significant differences in molecular abnormalities.

    The aim of this project is to look for statistically significant differences in molecular abnormalities from the three known genetic pathways, between the two different morphological types, granular and non-granular, to potentially demonstrate that these different polyps form via different genetic pathways.

    Time frame: Specimens will be stored and used for up to 15 years

07

Study locations

1 site
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01556399
Lead sponsor
Professor Michael Bourke
Responsible party
Professor Michael Bourke (Director of Gastrointestinal Endoscopy, Western Sydney Local Health District) — Sponsor-investigator
First posted
Mar 16, 2012
Start date
Nov 2011
Primary completion
Nov 2017
Completion
Nov 2018
Last update
Mar 27, 2025

Study contacts

Michael Bourke, MBBS, FRACP
principal investigator · Western Sydney Local Health District

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion